硼替佐米联合沙利度胺及地塞米松治疗多发性骨髓瘤的疗效观察

Efficacy observation of bortezomib combined with thalidomide and dexamethasone in the treatment of multiple myeloma

目的探究硼替佐米联合沙利度胺及地塞米松治疗多发性骨髓瘤的临床疗效。方法74例多发性骨髓瘤患者,依据随机数字表法分为研究组与对照组,各37例。对照组患者应用长春新碱+阿霉素+地塞米松治疗,研究组患者应用硼替佐米+沙利度胺+地塞米松治疗。比较两组临床疗效,不良反应发生情况,治疗前后血清M蛋白、β_(2)微球蛋白水平。结果研究组治疗总有效率91.89%高于对照组的72.97%,差异有统计学意义(P<0.05)。研究组不良反应发生率5.41%明显低于对照组的21.62%,差异有统计学意义(P<0.05)。治疗后,研究组血清M蛋白(26.87±5.44)g/L、β_(2)微球蛋白(4.54±1.24)mg/L均低于对照组的(30.76±8.76)g/L、(6.25±1.54)mg/L,差异有统计学意义(P<0.05)。结论硼替佐米联合沙利度胺及地塞米松可作为重要的治疗方案之一,广泛推广应用于多发性骨髓瘤的临床治疗中。

Objective To investigate the clinical efficacy of bortezomib combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Methods A total of 74 patients with multiple myeloma were divided into study group and control group according to the random numerical table,with 37 cases in each group.The control group was treated with vinnestine+adriamycin+dexamethasone,while the study group was treated with bortezomib+thalidomide+dexamethasone.The clinical efficacy,occurrence of adverse reactions,serum M protein andβ_(2) microglobulin levels before and after treatment were compared between the two groups.Results The total effective rate of 91.89%in the study group was higher than that of 72.97%in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 5.41%,which was significantly lower than that of 21.62%in the control group,and the difference was statistically significant(P<0.05).After treatment,the serum M protein of(26.87±5.44)g/L andβ_(2) microglobulin of(4.54±1.24)mg/L in the study group were lower than those of(30.76±8.76)g/L and(6.25±1.54)mg/L in the control group,and the differences were statistically significant(P<0.05).Conclusion Bortezomib combined with thalidomide and dexamethasone can be widely used in the clinical treatment of multiple myeloma as one of the important therapeutic options.